Lawrence D. Horwitz
About
In The Last Decade
Lawrence D. Horwitz
156 papers receiving 4.4k citations
Peers
Comparison fields: 5 of 131
- Cardiology and Cardiovascular Medicine 1.7k
- Pathology and Forensic Medicine 930
- Physiology 771
- Molecular Biology 755
- Surgery 710
Countries citing papers authored by Lawrence D. Horwitz
This map shows the geographic impact of Lawrence D. Horwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence D. Horwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence D. Horwitz more than expected).
Fields of papers citing papers by Lawrence D. Horwitz
This network shows the impact of papers produced by Lawrence D. Horwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence D. Horwitz. The network helps show where Lawrence D. Horwitz may publish in the future.
Co-authorship network of co-authors of Lawrence D. Horwitz
This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence D. Horwitz. A scholar is included among the top collaborators of Lawrence D. Horwitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence D. Horwitz. Lawrence D. Horwitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 10 | |
| 2 | 6 | |
| 3 | 19 | |
| 4 | 7 | |
| 5 | A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. | 32 |
| 6 | 14 | |
| 7 | 22 | |
| 8 | Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension. | 6 |
| 9 | 35 | |
| 10 | 16 | |
| 11 | 11 | |
| 12 | 4 | |
| 13 | 6 | |
| 14 | 6 | |
| 15 | 5 | |
| 16 | 6 | |
| 17 | 52 | |
| 18 | Factors influencing cardiac performance. | 11 |
| 19 | 4 | |
| 20 | 48 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.